First Trust Advisors LP Lowers Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

First Trust Advisors LP lessened its holdings in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 50.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 10,893 shares of the medical instruments supplier's stock after selling 11,304 shares during the period. First Trust Advisors LP's holdings in ICU Medical were worth $1,690,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Harvest Fund Management Co. Ltd purchased a new stake in ICU Medical during the fourth quarter valued at approximately $33,000. Murphy & Mullick Capital Management Corp purchased a new stake in shares of ICU Medical during the 4th quarter valued at $52,000. Venturi Wealth Management LLC boosted its position in shares of ICU Medical by 64.0% in the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier's stock worth $82,000 after purchasing an additional 206 shares in the last quarter. Russell Investments Group Ltd. increased its position in ICU Medical by 88.8% during the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 300 shares in the last quarter. Finally, Sterling Capital Management LLC raised its stake in ICU Medical by 813.5% in the fourth quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier's stock valued at $105,000 after buying an additional 602 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.

ICU Medical Stock Performance

Shares of ICUI stock traded down $4.57 during trading hours on Friday, hitting $138.30. The company's stock had a trading volume of 622,758 shares, compared to its average volume of 274,808. The stock has a market cap of $3.40 billion, a PE ratio of -30.26 and a beta of 0.87. ICU Medical, Inc. has a 12-month low of $100.91 and a 12-month high of $196.26. The company has a 50 day moving average of $140.67 and a 200 day moving average of $155.29. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The firm had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. During the same period in the previous year, the firm earned $0.96 EPS. The business's quarterly revenue was up 6.7% on a year-over-year basis. On average, sell-side analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ICUI. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Raymond James lowered their price objective on shares of ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating for the company in a research note on Friday. Finally, KeyCorp cut their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $192.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.